ASAIO 65 th Annual Conference Dare to Innovate Shape the Future June 26 29, 2019 San Francisco

Transcription

1 Preliminary Program Outline 2019 December 21, 2018 Subject to regular revision ASAIO 65 th Annual Conference Dare to Innovate Shape the Future June 26 29, 2019 San Francisco 8:30am 4:30pm ASAIO 8 th Annual Pediatric Medical Device Day Wednesday, June 26 th Breaking Barriers for Pediatric Breakthroughs Pediatric Day Chairs: Christina VanderPluym, MD, Boston Children s Hospital, Boston, MA Angela Lorts, MD, Cincinnati Children s Hospital Med. Ctr., Cincinnati, OH Nicole Gillette, BS, FDA, Silver Spring, MD Pediatric Day Session 1: Finding the Ideas to Fuel Pediatric Innovation Innovators Forum Pediatric Day Session 2: Finding Money to Fund Pediatric Innovation Device Consortia Governmental Bodies and Grants NIH/NHLBI Economics of Pediatric Device Development Venture Capital / Angel Investigator Pediatric Day Session 3: Finding the Way to Evaluate Pediatric Innovations International Collaborations in Regulatory Bodies: Why and What Can We Do With It? Pediatric Medical Device Life Cycle What Are the Steps? Alternative Strategies to Pediatric Device Evaluation Pediatric Day Session 4: Bringing Innovations to Our Pediatric Patients How to Bring A Device to Market? Centers for Devices and Radiologic Health Advancing Pediatric Mission The Ongoing Prolific Use of Off Label Devices: Implications for Us and Our Patients Ethical Challenges of Using Novel Technologies in Children: How to Start and When to Stop 8:00am 5:00pm ASAIO MCS/VAD University Wednesday, June 26 th Course Co-Chairs: Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN Daniel Timms, PhD, BiVACOR, Houston, TX Session 1: History, Fundamentals, and Indication for Durable MCS Therapy Session 2: Acute and Durable Support for INTERMACS I Patients? Acute Management of Shock in Crashing and Burning Patients Technology for the Care of Right Ventricular Failure: Indications and Options Recovery, Heart Transplantation, Timing, and Strategies for Transition to Durable Support Durable Left Ventricular Support and TAH

2 Session 3: The GOOD, The BAD, and UGLY in Durable Device Therapy Perioperative Management and Getting Through the First 30 Days Complications, Treatment Strategies and How Design (Waveforms) Can Help Management Session 4: Technology, Entertainment, Design (TED) Style MCS Dealing With A Thromboembolic Complication Recognition and Treatment of Aortic Insufficiency of Durable Device Placement Evaluation, Implications, and Management of Concomitant Coronary Disease Bridge to Heart Failure - Evaluation and Treatment After Durable Device Placement Session 5: Fundamental Principles and Engineering Advances to Enhance Technology Hemocompatibility and Outcomes Session 6: Heart Transplantation and Challenges in Bridged Patients Organ Selection in Patients Bridged With an LVAD: Implications of New UNOS Allocation System Destination Therapy vs High Risk Heart Transplantation in Older Patients / Patients With Device Complications Session 7: When Device Therapy Goes Wrong Management of Non-Compliant Patients: Implications and Importance of Social Environment Dealing With Devastating Complications on Support Palliative Care Role and End of Life Discussions Session 8: Man or Machine: Managing Interaction and Interface Between MCS and Patients MCS Performance Diagnostics and Matching Physiologic Demand Usability of MCS What s Going Wrong With Our Field? Review of FDA Maude Database ASAIO/ICCAC MCS Proficiency Verification Course (MPV) Wednesday, June 26 th ASAIO ICCAC MPV Co -Chairs: Dawn Christensen, MS, FNP-BC, Innovative Program Solutions, LLC, Pine Grove, PA Amanda Thomas, RN, BSN, Oregon Health & Science University Hospital, Portland, OR This Course features problem based scenarios covering management and troubleshooting of common issues surrounding MCS devices. Small group exercises are led by experienced MCS coordinators, Heart Failure Cardiologists, and Cardiac Surgeons who specialize in MCS support. There will be a minimum of eight small groups with a maximum of twelve participants each. Medtronic HVAD Abbott HeartMate II and HeartMate 3 Abbott Centrimag Berlin Heart EXCOR Abiomed - Impella SynCardia TAH

3 8:00am 12:00pm General Session 1 Thursday, June 27 th Top Graded Abstract Presentations Six Presentations Cardiac Bioengineering Pediatric Pulmonary Renal Nursing ASAIO President s Address - Steven Koenig, PhD, University of Louisville Keynote Address - Carrie Byington, MD, Texas A&M University Engineering Medicine: Developing Physicianeers to Shape the Future of Healthcare Through Innovation Medical Device Entrepreneur s Forum - MDEF 8:00am 12:00pm General Session 2 Friday, June 28 th ASAIOfyi- for young innovators - Rapid Fire Abstract Presentations ASAIOfyi-for young innovators - Student Design Competition Keynote Address Charles Fraser, MD, University of Texas at Austin Mechanical Circulatory Support in Children: Still a Long Way to Go ASAIO Hastings Lecture William Holman, MD, University of Alabama at Birmingham Innovation in Medical Devices: Lessons from the Past for Planning Our Future ASAIO History Group Scientific Biography Cardiac Sessions Thursday, Friday & Saturday Cardiac Chairs: Claudius Mahr, DO, FACC, FESC, University of Washington, Seattle, WA William Cotts, MD, MS, FACC, Advocate Christ Medical Center, Oak Lawn, IL Veli Topkara, MD, Columbia University, New York, NY Cardiac 1: The Future of MCS Panel The Future of MCS Cardiac 2: Reducing Neurologic Complications in MCS Panel Reducing Neurologic Complications in MCS

4 Cardiac 3: Acute Heart Failure and Cardiogenic Shock Panel Acute Heart Failure and Cardiogenic Shock Cardiac 4: The Future of Advanced Heart Failure: VAD vs Transplant Debate: The Future is Transplant Vs. The Future is VAD Cardiac 5: Pulsatility, Blood Pressure, Speed Optimization Panel Pulsatility, Blood Pressure, Speed Optimization Cardiac 6: RV Failure and BiV Failure in the Era of Centrifugal Flow Panel RV Failure and BiV Failure in the Era of Centrifugal Flow Bioengineering Sessions Thursday, Friday & Saturday Bioengineering Chairs: John Criscione, MD, PhD, Texas A&M University, College Station, TX Daniel Timms, PhD, BiVACOR, Houston, TX Kiyotaka Fukamachi, MD, PhD, Cleveland Clinic, Cleveland, OH Bioengineering 1: Device Innovation Device Innovation followed by Discussion Bioengineering 2: Modeling Innovation The Progression of Modeling in Medical Device Development Emerging Regulatory Frameworks for Modeling CFD and VAD Design Engineering Abstracts Bioengineering 3: Technical Controversy: Pulse or Not Physiologic Perspective Engineering Perspective Discussion Bioengineering 4: Artificial Organs and Tissue Engineering Myocardial Recovery and Tissue Engineering Tissue Engineered Vessels Discussion

5 Bioengineering 5: Innovation InSight Artificial Eye Development Innovations in Optical Pressure Sensors Discussion Bioengineering 6: Ex-Vivo Perfusion Models Are We Ready to Replace in-vivo Models With ex-vivo Ones? Discussion Pulmonary Sessions Thursday, Friday & Saturday Pulmonary Chairs: Dongfang Wang, MD, PhD, Univ of Kentucky College of Medicine, Lexington, KY Keshava Rajagopal, MD, PhD, University of Texas Health Science Center, Houston, TX Steven Conrad, MD, PhD, Louisiana State University HCS, Shreveport, LA Pulmonary 1: Bioengineering Conundrums in Artificial Lung Development: Blood Trauma, Thrombogenicity, and Biocompatibility Shear Stress and Blood Trauma, Stagnancy and Thrombosis Advanced Coating for Long -term Membrane Gas Exchange Pulmonary Abstracts Pulmonary 2: New Technology for Extracorporeal Lung Support Pittsburgh Paracorporeal Ambulatory Assist Lung The Osaka Ultra Compact Durable ECMO System Pulmonary Abstracts Pulmonary 3: VA ECMO for Resuscitation of Massive Pulmonary Embolism (PE) Massive Pulmonary Embolism Patients Receiving VA ECMO: Survivors vs Non-Survivors Large Volume Retrospective Study: VA ECMO Resuscitation for Massive Pulmonary Embolism Pulmonary Abstracts Pulmonary 4: Extracorporeal Lung Support/Ambulatory Artificial Lung for End Stage Lung Diseases Overview of Outcomes Data on ECMO Bridging to Lung Transplantation Cannulation Strategies for ECMO Bridging in the Lung Transplant Context How to Approach Individual Scenarios Development of Durable ECMO and ICMO Systems Pulmonary 5: Innovative Technologies for Respiratory Support Intravascular Oxygenation: Past and Potential for the Future Use of Microbubbles As An Approach to Blood Oxygenation 3D Printing of Artificial Lungs

6 Pulmonary 6: Controversies in Artificial Lung Support Roles for ECMO In Traumatic Respiratory Failure Pharmacological Treatment of Recirculation-Related Hypoxemia On V-V ECMO Respiratory Failure With Shock Responsive To Pharmacotherapy: V-V ECMO and Pharmacotherapy versus V-A ECMO? Respiratory Failure In the Obese: ECMO Outcomes? Renal Sessions Thursday, Friday & Saturday Renal Chairs: Lenar Yessayan, MD, University of Michigan, Troy, MI Balazs Szamosfalvi, MD, University of Michigan, Ann Arbor, MI Renal 1: Vascular Access: Innovative Devices The Ellipsys Vascular Access System An Update On Intergraft Trial Humacyte, A Founder s Experience Innovation In Catheter Design From The Palindrome to the Pristine Cather Renal 2: Cardiac Assist Devices, What the Nephrologist Needs to Know: Device Characteristics, Cannulation and Complications Ventricle Assist Devices Total Artificial Heart ECMO and ECCO-R: Integration With CRRT and Early Clinical Use Management of Infection, Thrombosis, Fibrin Sheath and Biofilm Renal 3: Sensing Technologies Relevant to RRT And Clinical Use Ion Selective Sensing The MediBeacon System: An Optical Skin GFR Sensor The Piezo Ring: Continuous Blood Pressure Monitoring In Critically Ill and Injured Patients Detecting Hemodynamic Instability (AHI and Drive) Disposable Sterile Conductivity Sensors for CRRT and Home HD Renal 4: Innovative Approaches to Extracorporeal Renal Support With Clinical Application Ultrafiltration for Advanced Heart Failure Using Tablo Outside-In Hemofiltration for Prolonged Operation Without Clogging Hydrodynamics, Filter Designs and Challenges Remote Data Collection Systems In Home Dialysis: PD/HD Devices Data Analytics for Continuous Renal Replacement Therapy Renal 5: KHI: Enabling Technologies for Wearable Dialysis and Implanted Artificial Kidney Kidney Health Initiative Defining the Purpose and Mission Silicon Membranes for Wearable Dialysis Electro-oxidation As A Strategy for Urea Removal In the Dialysate Recycling Process Sorbent Technology

7 Renal 6: Emerging Strategies In Acute Kidney Injury and Extracorporeal Support Safe CRRT-RCA Prescribing: Relative Importance of Protocol Design vs Expertise Pilot Study of CRRT and MSC Cartridge to Promote Organ Healing in MODS With AKI Hemoadsorption by CytoSorb In Septic Patients Spectral Apheresis Machine - An Open Platform for CRRT and Hemoperfusion Pediatric Sessions Thursday & Friday Pediatric Chairs: Christina VanderPluym, MD, Boston Children s Hospital, Boston, MA Angela Lorts, MD, Cincinnati Children s Hospital Medical Ctr, Cincinnati, OH Nicole Gillette, BS, FDA, Silver Spring, MD Pediatric 1: The Pros and Cons to Achieving Pediatric Labeling: Do We Need It? FDA Perspective Industry Perspective Providers Perspective Open Panel Discussion and Forum Pediatric 2: ACTION Learning Collaborative for Pediatrics Improving VAD Related Stroke Outcomes: Learning Network Blood Pressure Monitoring and Control Efficient and Effective Anticoagulation Streamlining Comprehensive Communication Pediatric 3: Pediatric Perspective on Hemostasis, Thrombogenicity and Hemocompatibility Unique Aspects of Developmental Hemostasis FDA Consideration of Preclinical Hemocompatibility Dialysis and Hemocompatibility Pediatric 4: Pediatric Abstracts VAD Coordinator Sessions Thursday & Friday VAD Sessions Chairs: Lori Edwards, MSN, RN, INOVA Fairfax Hospital, Falls Church, VA Sarah Schroeder, ACNP-BC, MSN, Bryan Heart, Lincoln, NE VAD 1: Ideas to Evolve an MCS Program Change Is Good, Yet Why Do We Stay? Initiations, Transitions and Incorporations Orientation of VAD Coordinator Effects of New UNOS Criteria on VAD Programs FDA Decision Tree for MCS Therapy

8 VAD 2: Debates: Seasoned versus Junior Coordinators Emergent VAD Evaluations: A Reality or Should They Be Offered? Ethics: Just Because We Can, Should We? Controversy or Not: Legalized Marijuana and It s Effects On A VAD Program Critical Care / Anesthesiology / Pathology Dates to be determined CAP 1: Pathology of Cardiovascular Devices and the Clinical Translation Cardiovascular Pathology for Biomedical Engineers A Review of Thrombosis in a Device Context The Challenges of Anticoagulation Following Mechanical Circulatory Support Implantation What Did My Company Do Wrong? The FDA is Questioning My Pathology Report CAP 2: Pathology of Cardiovascular Devices and the Clinical Translation LVAD Pathology Perspective From A Clinician s Experience Pathology of An Implantable Cardiac Valve With A Bioresorbable Stent Scaffold Panel Discussion - Translational Medicine and the Importance of Multidisciplinary Scientific Collaboration in Medical Technology Development CAP 3: Topics in Critical Care and Anesthesiology Transesophageal Echocardiography for the Intra-operative Management of the LVAD Patient ICU Management of RV Failure After LVAD Placement Novel Pulmonary Vasodilators in the ICU CAP 3: Topics in Critical Care and Anesthesiology ARDS and Mechanical Ventilation The Interplay of Pulmonary Pathophysiology and Machine Support Cannulation Strategies for Difficult/Unusual ECMO Cases IFAO Session - Biomaterials Friday, June 28 t